Verdinexor

Indications

LAVERDIA is indicated for the treatment of lymphoma in dogs.

Dosage and Administration

Always provide the Client Information Sheet to the dog owner with each prescription. Dosing Instructions: 1. Feed the dog immediately before giving LAVERDIA. 2. Wear protective disposable chemotherapy resistant gloves when handling LAVERDIA (see USER SAFETY WARNINGS ). 3. Use an appropriate combination of tablets to administer the dose: a) Administer LAVERDIA at an initial dose of 1.25 mg/kg administered orally twice per week (e.g., Monday and Thursday or Tuesday and Friday) with at least 72 hours between doses. b) If tolerated after 2 weeks, increase the dose of LAVERDIA to 1.5 mg/kg twice per week with at least 72 hours between doses. c) Dose reductions of 0.25 mg/kg to a minimum dose of 1 mg/kg twice per week with at least 72 hours between doses or dose interruptions may be considered if the dog has adverse reactions (see ANIMAL SAFETY WARNINGS ,

Contraindications

Do not use in dogs that are pregnant, lactating or intended for breeding. LAVERDIA is a possible teratogen and can affect female and male fertility. Laboratory studies in the rat have shown reduced fertility, embryotoxicity, teratogenicity and maternal toxicity. Administration of LAVERDIA caused degeneration/atrophy and vacuolation in the seminiferous tubules and oligospermia in the epididymides in male dogs in the margin of safety study (see TARGET ANIMAL SAFETY ).

Warnings

USER SAFETY WARNINGS: NOT FOR USE IN HUMANS. KEEP THIS AND ALL MEDICATIONS OUT OF THE REACH OF CHILDREN. CHILDREN SHOULD NOT COME INTO CONTACT WITH LAVERDIA. Children should not come in contact with the feces, urine, vomit, or saliva of treated dogs. Pregnant women, women who may become pregnant, and nursing women should not handle or administer LAVERDIA or come in contact with the feces, urine, vomit, or saliva from LAVERDIA-treated dogs. Based on animal studies, LAVERDIA can cause birth defects and affect female fertility. LAVERDIA can affect male fertility based on animal studies and studies in humans. Wear protective disposable chemotherapy resistant gloves when handling LAVERDIA to avoid exposure to drug. Wear protective disposable chemotherapy resistant gloves to prevent direct contact with moistened, broken, or crushed LAVERDIA tablets. Wear protective disposable chemotherapy resistant gloves to prevent contact with feces, urine, vomit, and saliva during treatment and for 3 days after the dog has received the last treatment. Place all waste material in a plastic bag and seal before general disposal. Wash hands immediately and thoroughly with soap and water if contact with the feces, urine, vomit, or saliva from LAVERDIA-treated dogs occurs. Any items that come in contact with feces, urine, vomit, or saliva should not be washed with other laundry during treatment and for 3 days after the last treatment with LAVERDIA. Wear protective disposable chemotherapy resistant gloves when handling the dog’s toys, food bowl, and water bowl. Wash food and water bowls separately from other items during treatment and for 3 days after the dog has received the last treatment. If LAVERDIA is accidentally ingested, or if there is significant contact with feces, urine, vomit, or saliva of dogs during treatment or within 3 days after the last treatment without proper precautions, seek medical advice immediately. It is important to show the treating physician a copy of the package insert, label, or client information sheet. Special instructions for handling and administering the product • It is recommended that LAVERDIA be administered under the supervision of, or in consultation with, a veterinarian experienced in the use of cancer therapeutic agents. • Use standard measures for the safe handling of all chemotherapeutic drugs. Refer to Occupational Safety and Health Administration (OSHA) for appropriate guidelines, recommendations, and regulations for handling antineoplastic agents. • Do not eat, drink or smoke while handling the product. • Do not store near food, in or near a food preparation area, or with medications intended for use in humans. Skin contact • In case of contact with skin, wash the affected area immediately and thoroughly with soap and water. Accidental eye exposure • Rinse eyes with large amounts of tap water (use eyewash station if present) for 10 minutes while holding back the eyelid. • Remove contact lenses. • Seek medical advice immediately and show the package insert or label to the physician. Accidental oral exposure or ingestion • Seek medical advice immediately and show the package insert or label to the physician. ANIMAL SAFETY WARNINGS: LAVERDIA can cause severe anorexia. Dogs should be carefully monitored for inappetence, vomiting, diarrhea, dehydration and weight loss, and supportive care should be provided as clinically indicated (see ADVERSE REACTIONS ). In the studies used to support approval, appetite stimulants, anti-nausea medication, and corticosteroids (prednisone) were found to reduce the incidence of anorexia and gastrointestinal adverse reactions associated with LAVERDIA. Keep LAVERDIA in a secure location out of reach of dogs, cats, and other animals to prevent accidental ingestion or overdose.

Adverse Reactions

). 4. Do not split or crush tablets.

Information for Owners

Always provide the Client Information Sheet with each prescription and review it with the dog owner or person responsible for care of the dog. Advise dog owners about possible adverse reactions, when to contact a veterinarian, how to handle and administer the product, and how to clean up any feces, urine, vomit, or saliva from dogs treated with LAVERDIA. The Client Information Sheet also contains warnings for humans and what to do in case of accidental human exposure to LAVERDIA.

Storage

Store the bottles at controlled room temperature 20° to 25°C (68° – 77°F).

FDA adverse event reports

The FDA Center for Veterinary Medicine publishes the adverse event reports it receives through openFDA. The counts below are the reports naming verdinexor as an active ingredient for each species this label names, as returned on 2026-09-16, coded by the VeDDRA reaction term the reporter chose. Reactions are counted per report, so one report can appear under several terms.

These are counts, not rates. Reporting is voluntary, the number of animals treated is not known, and a widely used product accumulates reports for that reason alone. A report records that an event followed a dose; it does not establish that the product caused it. The counts say nothing about how one product compares with another.